{"nctId":"NCT02517515","briefTitle":"ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection","startDateStruct":{"date":"2015-07","type":"ACTUAL"},"conditions":["Hepatitis C Virus (HCV)"],"count":650,"armGroups":[{"label":"Double-blind 3-DAA","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir"]},{"label":"Double-blind Placebo Followed by Open-label 3-DAA","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir","Drug: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir"]}],"interventions":[{"name":"ombitasvir/paritaprevir/ritonavir and dasabuvir","otherNames":["Viekira Pak","paritaprevir also known as ABT-450","ombitasvir also known as ABT-267","dasabuvir also known as ABT-333"]},{"name":"Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chinese, South Korean, and Taiwanese descent with full Chinese, South Korean, and Taiwanese parentage\n* Chronic hepatitis C virus (HCV) infection prior to study enrollment.\n* Screening laboratory result indicating HCV subtype 1b (GT1b) infection.\n* Per local standard practice, documented absence of cirrhosis.\n* Participant has never received antiviral treatment (including interferon \\[IFN\\]-based therapy \\[alpha, beta or pegylated (peg)IFN\\] with or without RBV) for HCV infection (treatment-naïve participant) or participant must have documentation that they met the definition of one of the following categories (treatment experienced participant): Non-responder or Relapser\n* Participant has plasma HCV RNA level \\> 10,000 IU/mL at Screening.\n\nExclusion Criteria:\n\n* HCV genotype performed during screening indicating unable to genotype or infection with any HCV genotype other than GT1b.\n* Positive test result at Screening for hepatitis B surface antigen (HBsAg), or hepatitis B virus DNA (HBV-DNA) \\> Lower Limit of Quantification (LLOQ) if HBsAg negative, or anti-human immunodeficiency virus antibody (HIV Ab) positive.\n* Any current or past clinical evidence of cirrhosis.\n* Any primary cause of liver disease other than chronic HCV infection.\n* Screening laboratory analyses showing abnormal kidney, hepatic, or hematologic function.\n* Use of known strong inducers of cytochrome P450 3A (CYP3A) or strong inhibitors of cytochrome P450 3A (CYP2C8) within 2 weeks or within 10 half-lives, whichever is longer, of the respective medication/supplement prior to study drug administration.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of active study drug. The primary efficacy endpoint was superiority of the percentage of treatment-naïve and treatment-experienced HCV subgenotype 1b (GT1b)-infected participants treated with 3-DAA (ombitasvir/paritaprevir/ritonavir \\[25 mg/150 mg/100 once daily\\] and dasabuvir \\[250 mg twice daily\\]) who achieved SVR12 compared with the historical control rate for comparable patients treated with telaprevir (TVR) plus pegylated interferon (pegIFN) and RBV.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24)","description":"SVR24 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of active study drug. The primary efficacy endpoint was superiority of the percentage of treatment-naïve and treatment-experienced HCV subgenotype 1b (GT1b)-infected participants treated with 3-DAA (ombitasvir/paritaprevir/ritonavir \\[25 mg/150 mg/100 once daily\\] and dasabuvir \\[250 mg twice daily\\]) who achieved SVR24 compared with the historical control rate for comparable patients treated with telaprevir (TVR) plus pegylated interferon (pegIFN) and RBV.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \\< LLOQ during active treatment; confirmed increase of \\> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during active treatment; or all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of active treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse by Post-treatment Week 12","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of active study drug among participants who completed treatment with HCV RNA levels \\< LLOQ at the end of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse by Post-treatment Week 24","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 24 weeks after the last dose of active study drug among participants who completed treatment with HCV RNA levels \\< LLOQ at the end of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":325},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","HEADACHE","DIZZINESS","ABDOMINAL PAIN UPPER"]}}}